Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 21, Issue 4, Pages 413-424Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2021.1856660
Keywords
Apoptosis; BCL-2 family proteins; BH3-mimetics; cell death; malignant pleural mesothelioma
Categories
Funding
- National Health and Medical Research Council of Australia [GNT1157551]
- La Trobe University Post Graduate Research Scholarship
- Lung Foundation Australia
- Australian Research Council [FT150100212]
- Victorian Cancer Agency [MCRF19045]
- Australian Research Council [FT150100212] Funding Source: Australian Research Council
Ask authors/readers for more resources
With limited therapeutic options for malignant pleural mesothelioma (MPM), the over-expression of pro-survival BCL-2 family proteins has been identified as a potential mechanism for cell survival in MPM. BH3-mimetics targeting these proteins show promise as a novel treatment option, especially considering the lack of actionable oncogene driver mutations and limited benefit from immune checkpoint inhibition in MPM.
Introduction: With limited recent therapeutic changes, malignant pleural mesothelioma (MPM) is associated with poor survival and death within 12 months, making it one of the most lethal malignancies. Due to unregulated asbestos use in developing countries and home renovation exposures, cases of MPM are likely to present for decades. As MPM is largely driven by dysregulation of tumor suppressor genes, researchers have examined other mechanisms of subverting tumor proliferation and spread. Over-expression of pro-survival BCL-2 family proteins impairs cells from undergoing apoptosis, and BH3-mimetics targeting them are a novel treatment option across various cancers, though have not been widely investigated in MPM. Areas covered: This review provides an overview of MPM and its current treatment landscape. It summarizes the role of BCL-2 family proteins in tumorigenesis and the therapeutic potential of BH3-mimetics . Finally, it discusses the role of BCL-2 proteins in MPM and the pre-clinical rationale for investigating BH3-mimetics as a therapeutic strategy. Expert opinion: As a disease without readily actionable oncogene driver mutations and with modest benefit from immune checkpoint inhibition, novel therapeutic options are urgently needed for MPM. Hence, BH3-mimetics provide a promising treatment option, with evidence supporting dependence on pro-survival BCL-2 proteins for MPM cell survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available